MedPath

Tyrosine

Generic Name
Tyrosine
Brand Names
Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10
Drug Type
Small Molecule
Chemical Formula
C9H11NO3
CAS Number
60-18-4
Unique Ingredient Identifier
42HK56048U
Background

Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

Indication

Tyrosine is claimed to act as an effective antidepressant, however results are mixed. Tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies.

Associated Conditions
Acute Renal Dysfunction, Renal Failure, Chronic Renal Failure
Associated Therapies
Amino acid supplementation
Clinical Trials
Related News

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active, not recruiting
Conditions
Hepatic Arterial Infusion Chemotherapy
Tyrosine Kinase Inhibitor
Immune Checkpoint Inhibitors
Hepatocellular Carcinoma (HCC)
Interventions
Procedure: hepatic artery infusion chemotherapy
Drug: Immune Checkpoint Inhibitors
First Posted Date
2024-10-08
Last Posted Date
2024-10-08
Lead Sponsor
First Hospital of China Medical University
Target Recruit Count
97
Registration Number
NCT06632106
Locations
🇨🇳

The first hospital of China medical university, Shenyang, Liaoning, China

HRQOL in Locally Advanced Thyroid Carcinoma

Recruiting
Conditions
Health Related Quality of Life
Tyrosine Kinase Inhibitor
Thyroid Cancer
Interventions
First Posted Date
2023-04-21
Last Posted Date
2023-04-21
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
80
Registration Number
NCT05824312
Locations
🇨🇳

Road Fuma No.420, Fuzhou, Fujian, China

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene

Phase 1
Terminated
Conditions
Hepatocellular Carcinoma
Solid Tumor
Hepatocellular Carcinoma Non-resectable
Hepatocellular Carcinoma Recurrent
Hepatocellular Cancer
Liver Cancer
Liver, Cancer Of, Non-Resectable
Interventions
Drug: Checkpoint Inhibitor, Immune
First Posted Date
2022-08-11
Last Posted Date
2025-02-03
Lead Sponsor
Omega Therapeutics
Target Recruit Count
24
Registration Number
NCT05497453
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

University of Florida Health Cancer Center, Gainesville, Florida, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 12 locations

Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

First Posted Date
2022-05-19
Last Posted Date
2024-11-13
Lead Sponsor
CStone Pharmaceuticals
Target Recruit Count
61
Registration Number
NCT05381753
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Phase 3
Recruiting
Conditions
Driver Mutation Positive Non-small Cell Lung Cancer
Asymptomatic Brain Metastases
Interventions
Radiation: Stereotactic radiosurgery/whole brain radiotherapy
First Posted Date
2022-02-11
Last Posted Date
2023-04-12
Lead Sponsor
Tata Memorial Hospital
Target Recruit Count
190
Registration Number
NCT05236946
Locations
🇮🇳

Tata Memorial Hospital, Mumbai, Maharashtra, India

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Phase 2
Not yet recruiting
Conditions
HER2-positive Breast Cancer
Brain Metastases
Interventions
Drug: Taxanes
First Posted Date
2021-02-18
Last Posted Date
2021-06-02
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
120
Registration Number
NCT04760431
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China

🇨🇳

Peking University International Hospital, Beijing, Beijing, China

Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation

Not Applicable
Completed
Conditions
Stress, Psychological
Interventions
Biological: Blood collection
Device: Photoplethysmography
Behavioral: Psychological questionnaires
Drug: Placebo
First Posted Date
2020-09-16
Last Posted Date
2022-11-25
Lead Sponsor
Direction Centrale du Service de Santé des Armées
Target Recruit Count
116
Registration Number
NCT04549194
Locations
🇫🇷

Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France

Contribution of L-Tyrosine to Human Decision Making in Stressful Situations

Not Applicable
Completed
Conditions
Stress, Psychological
Interventions
Biological: Blood collection
Drug: Placebo
Behavioral: Cognitive tasks
Behavioral: Anxiety scale
Other: Stress exposure
Device: Electromyography (EMG)
Device: Electroencephalography (EEG)
First Posted Date
2020-08-19
Last Posted Date
2022-11-25
Lead Sponsor
Direction Centrale du Service de Santé des Armées
Target Recruit Count
17
Registration Number
NCT04518254
Locations
🇫🇷

Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

First Posted Date
2020-06-19
Last Posted Date
2020-06-19
Lead Sponsor
wang, jianxiang
Target Recruit Count
50
Registration Number
NCT04440267
Locations
🇨🇳

HBDH, Tianjin, Tianjin, China

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

Completed
Conditions
Renal Cell Carcinoma (RCC)
Interventions
Drug: Immuno-oncology (IO)
First Posted Date
2020-05-05
Last Posted Date
2023-04-06
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT04375150
Locations
🇺🇸

Pfizer INC, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy